Lymphoma

Adding rituximab to chemotherapy does not influence response in older patients

Published in Cancer Weekly, December 30th, 2003

Adding rituximab to the standard chemotherapy regimen for lymphoma patients, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), does not significantly increase survival in older patients with diffuse large B-cell lymphoma, according to a study presented during the 45th Annual Meeting of the American Society of Hematology (ASH).

Rituximab is a monoclonal antibody used to treat certain lymphomas that have lymphocytes with the CD20 receptor.

The research team, headed by Thomas Habermann, MD, of the Eastern Cooperative Oncology Group, Boston, concluded that the addition of rituximab to the CHOP regimen as a first-line treatment did not...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry